嘉和生物-B:被许可人于其许可引入的新型T细胞衔接器用于自身免疫性疾病临床评估方面取得进展

格隆汇
Jun 30

格隆汇6月30日丨嘉和生物-B(06998.HK)宣布,公司获GB261的被许可人Candid Therapeutics, Inc.("被许可人")告知,被许可人于其许可引入的新型T细胞衔接器("TCE"或"GB261")用于自身免疫性疾病临床评估方面取得进展。首批患者已接受TCE给药且耐受性良好。此外,TCE的皮下给药配方已经确定。GB261是一种针对B细胞上的CD20与T细胞上的CD3而开发的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10